ChromaDex Supplies ‘Healthy Aging’ Ingredient To Male Supplement Brand
Executive Summary
ChromaDex Corp. agrees to supply its ‘healthy aging’ nicotinamide riboside ingredient Niagen to New York-based healthcare technology firm Roman Health Ventures, Inc., which plans to use it in its men’s supplement line. ChromaDex’ total sales in the first quarter rose 2% to $14.7m.
You may also be interested in...
ChromaDex TV Ads Increase Sales, Customer Base
Tru Niagen sales made up more than 85% of first-quarter total, and TV ads launched in March drove a “dramatic increase” in customers, says CEO Robert Fried.
ChromaDex Invests In Tru Niagen TV Ads As Study Results Spur Word-Of-Mouth Promotion
Firm emphasizes TV advertising spending and Walmart-related commercial launching in March in its earnings briefing. “We could go much broader than just sort of a male fitness sports-related cohort. We think it's a much broader-based market than that,” says CEO Robert Fried.
Phase II Of Parkinson’s Treatment Trial Starts For ChromaDex's Nicotinamide Riboside
ChromaDex completed its phase I clinical trial studying the effects of nicotinamide riboside on Parkinson’s Disease. Lead researcher Charalampos Tzoulis is “very excited about these results” and that the trial represents “a novel approach in experimental PD-therapy.”